

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information

## **Olerup SSP® HLA-B\*54**

Product number:	101.569-06 – including <i>Taq</i> polymerase 101.569-06u – without <i>Taq</i> polymerase
Lot number:	7E8
Expiry date:	2019-05-01
Number of tests:	6
Number of wells per test:	21+1
Storage - pre-aliquoted primers:	dark at -20°C
- PCR Master Mix:	-20°C
- Adhesive PCR seals	RT
- Product Insert	RT

### **This Product Description is only valid for Lot No. 7E8.**

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

### **CHANGES COMPARED TO THE PREVIOUS OLERUP SSP® HLA-B\*54 LOT (49Y)**

The HLA-B\*54 kit is updated for new alleles to enable separation of:

- Confirmed<sup>1</sup> alleles as listed in the IMGT/HLA database
- Polymorphisms in exons outside of the region encoding the peptide binding domain
- Null and Alternatively expressed alleles

<sup>1</sup>As described in section Uniquely Identified Alleles.

The HLA-B\*54 specificity and interpretation tables have been updated for the HLA-B alleles described since the previous *Olerup SSP®* HLA-B\*54 lot was made (**Lot No. 49Y**). The kit design is based on IMGT/HLA database 3.25.0.

As of lot series V, the Specificity Table is included in the lot-specific Product Insert, and the Interpretation Table is included in the Worksheet.

The HLA-B\*54 primer set is unchanged compared to the previous lot.

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information

Well **22** contains Negative Control primer pairs, that will amplify more than 95% of the Olerup SSP® HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.  
The PCR product generated by the positive control primer pair is 430 base pairs.

Length of PCR product	105	200	105	80	75	80	85
<b>5'-primer<sup>1</sup></b>	<b>164</b>	<b>340</b>	<b>440</b>	<b>45</b>	<b>45</b>	<b>43</b>	<b>36</b>
	5'-CAC <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-TTA <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-TAC <sup>3'</sup>
							36
							5'-TAT <sup>3'</sup>
<b>3'-primer<sup>2</sup></b>	<b>231</b>	<b>2<sup>nd</sup> I</b>	<b>507</b>	<b>59</b>	<b>58</b>	<b>57</b>	<b>47</b>
	5'-TgC <sup>3'</sup>	5'-AAA <sup>3'</sup>	5'-TTg <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ACA <sup>3'</sup>
							48
							5'-gCA <sup>3'</sup>
							48
							5'-gCC <sup>3'</sup>
							52
							5'-TgT <sup>3'</sup>
<b>A*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>B*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>C*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>DRB1</b>				<b>+</b>	<b>+</b>		
<b>DRB3</b>				<b>+</b>	<b>+</b>		
<b>DRB5</b>				<b>+</b>			
<b>DQB1</b>					<b>+</b>		
<b>DPB1</b>						<b>+</b>	
<b>DQA1</b>							<b>+</b>

<sup>1</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>2</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon or the 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information

## PRODUCT DESCRIPTION

### HLA-B\*54 SSP subtyping

#### CONTENT

The primer set contains 5'- and 3'-primers for identifying the B\*54:01 to B\*54:35 alleles.

#### PLATE LAYOUT

Each test consists of 22 PCR reactions in a 24 well PCR plate. Wells 23 to 24 are empty.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	16
17	18	19	20	21	NC	empty	empty

The 24 well PCR plate is marked with 'HLA-B\*54' in silver/gray ink.

Well No. 1 is marked with the Lot Number '7E8'.

Wells 1 to 21 – HLA-B\*54 high resolution primers.

Well 22 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are covered with a PCR-compatible foil.

**Please note:** When removing each 24 well PCR plate, make sure that the remaining plates stay covered. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

#### INTERPRETATION

Due to the sharing of sequence motifs between HLA-B alleles, non-HLA-B\*54 alleles will be amplified by primer mixes 1 to 6, 8 to 12, 14, 15 and 17 to 19. In addition, a few HLA-A and HLA-C alleles will be amplified by primer mixes 3 to 5, 9, 13, 15 and 17.

For further details see Specificity Table.

#### UNIQUELY IDENTIFIED ALLELES

All the HLA-B\*54 alleles, i.e. **B\*54:01 to B\*54:35**, recognized by the HLA Nomenclature Committee in July 2016<sup>1,2</sup> will be amplified by the primers in the HLA-B\*54 subtyping kit.

The HLA-B\*54 kit enables separation of the confirmed HLA-B\*54 alleles as listed in the IMGT/HLA database. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-B\*54 alleles is listed below.

The HLA-B\*54 kit also enables identification of polymorphisms in exons outside of the region encoding the peptide binding domain and of null and alternatively expressed alleles.

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information

The following HLA-B\*54 alleles can be distinguished by the different sizes of the HLA-specific PCR product:

Alleles	Primer mix
B*54:17, B*54:18	16

The HLA-B\*54 subtyping kit cannot distinguish the following silent mutations: the B\*54:01:01 and B\*54:01:03-54:01:07 alleles.

<sup>1</sup>HLA-B alleles listed on the IMGT/HLA web page 2016-July-14, release 3.25.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

<sup>2</sup>Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

## ALLELE CONFIRMATION STATUS

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
<b>B*54:01:01</b>	<b>Confirmed</b>	B*54:15	Unconfirmed	B*54:35	Unconfirmed
B*54:01:02	Unconfirmed	B*54:16	Unconfirmed		
B*54:01:03	Unconfirmed	B*54:17	Unconfirmed		
B*54:01:04	Unconfirmed	B*54:18	Unconfirmed		
B*54:01:05	Unconfirmed	B*54:19	Unconfirmed		
B*54:01:06	Unconfirmed	B*54:20	Unconfirmed		
B*54:01:07	Unconfirmed	B*54:21	Unconfirmed		
B*54:02	Unconfirmed	B*54:22	Unconfirmed		
B*54:03	Unconfirmed	B*54:23	Unconfirmed		
B*54:04	Unconfirmed	B*54:24	Unconfirmed		
B*54:05N	Unconfirmed	B*54:25	Unconfirmed		
B*54:06	Unconfirmed	B*54:26	Unconfirmed		
B*54:07	Unconfirmed	B*54:27	Unconfirmed		
B*54:08N	Unconfirmed	B*54:28	Unconfirmed		
B*54:09	Unconfirmed	B*54:29	Unconfirmed		
<b>B*54:10</b>	<b>Confirmed</b>	B*54:30	Unconfirmed		
B*54:11	Unconfirmed	B*54:31	Unconfirmed		
B*54:12	Unconfirmed	B*54:32	Unconfirmed		
<b>B*54:13</b>	<b>Confirmed</b>	B*54:33	Unconfirmed		
<b>B*54:14</b>	<b>Confirmed</b>	B*54:34	Unconfirmed		

<sup>1</sup>Allele status “confirmed” or “unconfirmed” as listed on the IMGT/HLA web page 2016-July-14, release 3.25.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

## RESOLUTION IN HOMO- AND HETEROZYGOTES

Results file with resolution in HLA-B\*54 homo- and heterozygotes is available upon request.

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information  
**SPECIFICITY TABLE**

**HLA-B\*54 SSP subtyping**

**Specificities and sizes of the PCR products of the 21+1 primer mixes used for HLA-B\*54 SSP subtyping**

Primer Mix	Size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	Amplified HLA-B*54 alleles <sup>3</sup>	Other amplified HLA Class I alleles <sup>4</sup>
1	215 bp	<b>800 bp</b>	*54:01:01, 54:01:03-54:35	*07:02:19, 15:01:04, 18:01:20, 18:72:02, 37:01:04, 40:94, 51:01:18, 55:02:07, 58:01:08
2 <sup>5</sup>	105 bp	1070 bp	*54:01:01-54:03, 54:05N, 54:07- 54:08N, 54:10, 54:12-54:13, 54:16- 54:30, 54:32-54:35	*07:78, 13:02:01-13:02:14, 13:02:16-13:03, 13:08-13:09, 13:14-13:16, 13:18-13:19, 13:27, 13:30-13:34, 13:37-13:38, 13:40-13:42, 13:44- 13:45, 13:48-13:49N, 13:53-13:56:02N, 13:58, 13:65-13:70, 13:74-13:75, 13:81-13:82, 13:84- 13:85, 13:88-13:89, 13:91, 13:93, 14:37, 15:42, 15:303, 35:60, 44:15, 44:18, 45:01:01-45:01:02, 45:03-45:08, 45:10-45:19, 46:11, 46:18, 49:01:01-49:03, 49:06-49:14, 49:16-49:17, 49:19N-49:43, 50:01:01-50:02, 50:04-50:08, 50:10-50:11, 50:13, 50:15, 50:18-50:19, 50:31- 50:32, 50:34-50:40, 50:43-50:47, 51:15, 51:157, 52:25:01, 55:01:01-55:01:03, 55:01:05-55:01:06, 55:01:08-55:03, 55:05, 55:07, 55:09-55:12, 55:15-55:16, 55:18-55:19, 55:21-55:22, 55:24- 55:26, 55:29-55:31, 55:33-55:38, 55:40-55:41, 55:43, 55:45-55:48, 55:50, 55:52, 55:54-55:57, 55:59-55:60, 55:62-55:67, 55:69-55:78, 56:01:01:01-56:01:08, 56:07-56:08, 56:13-56:14, 56:16-56:17, 56:19N-56:20:02, 56:23-56:30, 56:33-56:49, 59:01:01:01-59:01:01:02, 59:04- 59:09
3 <sup>6</sup>	160 bp	1070 bp	*54:01:01-54:01:07, 54:03-54:04, 54:06- 54:35	*08:101, 44:24, 44:181, 51:39, <b>C*05:30,</b> <b>C*06:125, C*07:441, C*16:86</b>
4 <sup>7</sup>	160 bp	1070 bp	*54:02, 54:19	*07:13, 07:110, 37:52, 38:11, 48:36, 67:02, 81:06, <b>C*03:137, C*03:182, C*07:102<sup>w</sup>,</b> <b>C*07:351, C*12:82</b>
5	180 bp	1070 bp	*54:03, 54:08N, 54:33	*13:03, 13:48, 15:73, 15:303, 40:71, 44:10, 44:15, 44:18, 44:140, 45:01:01-45:01:02, 45:04- 45:07, 45:11-45:19, 46:11, 49:01:01-49:01:07, 49:02-49:03, 49:06, 49:08-49:14, 49:16-49:17, 49:19N-49:43, 50:01:01-50:02, 50:04-50:08, 50:10-50:13, 50:15-50:19, 50:32, 50:34-50:38, 50:40-50:44, 50:46-50:47, 51:15, 51:62, 51:106, 52:25:01-52:25:02, 56:01:01:01-56:01:04, 56:01:06-56:02:02, 56:04, 56:07-56:08, 56:13- 56:14, 56:16-56:17, 56:20:01-56:20:02, 56:24- 56:30, 56:33-56:49, 56:51, 58:73, 59:04, 82:01- 82:03, <b>C*03:19, C*03:102</b>
6 <sup>5</sup>	105 bp	1070 bp	*54:04, 54:11, 54:15	*07:84, 08:09, 08:84, 13:35, 13:59, 13:62, 15:83, 27:14, 27:81, 27:130, 27:153, 35:273, 40:06:01:01-40:06:08, 40:06:10-40:06:15, 40:44,

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information

				40:53, 40:70:01-40:70:02, 40:75, 40:83, 40:93, 40:95-40:96, 40:103, 40:109-40:110, 40:127, 40:131, 40:148, 40:161-40:162, 40:165, 40:167, 40:177, 40:190, 40:230, 40:244, 40:256N, 40:268-40:270, 40:275, 40:294-40:295, 40:298, 40:306-40:307, 40:311, 40:313, 40:317-40:318, 41:01:01-41:01:04, 41:05-41:07, 41:09, 41:12, 41:14, 41:16-41:17, 41:20-41:22, 41:25-41:26, 41:28-41:29, 41:32-41:35, 41:37, 42:04, 44:20, 44:47, 44:100, 44:197, 49:18:01-49:18:02, 50:14, 50:20, 51:01:01:01-51:01:47, 51:01:49-51:03, 51:05, 51:07:01-51:12, 51:14, 51:16-51:24:05, 51:26-51:34, 51:36, 51:38-51:41N, 51:43-51:44N, 51:48-51:55, 51:57-51:58, 51:60-51:61:02, 51:65-51:80, 51:82-51:91, 51:93-51:96, 51:98N, 51:100-51:105, 51:107-51:130, 51:132, 51:134, 51:136-51:138, 51:140-51:147, 51:149N-51:156, 51:158:01-51:171, 51:173Q-51:193, 51:195-51:208, 52:01:01:01-52:13, 52:15-52:24, 52:26-52:38, 52:40-52:61, 55:17, 55:20, 55:27-55:28, 56:05:01-56:06, 56:15, 56:21, 58:08:01-58:08:02, 59:02, 78:01:01-78:09
	235 bp		*54:08N	
<b>7</b>	140 bp	1070 bp	*54:05N	
<b>8</b>	280 bp	1070 bp	*54:06, 54:09, 54:14	*07:09, 07:11, 07:17, 07:162, 07:235, 07:237, 07:255, 08:28, 08:35, 08:37, 08:89, 08:107, 13:04, 13:10, 13:26:01-13:26:02, 13:72, 15:01:01:01-15:01:04, 15:01:06-15:08:02, 15:11:01-15:16:03, 15:18:01:01-15:21, 15:23-15:29, 15:31-15:36, 15:38:01-15:40:02, 15:43-15:44, 15:46-15:47:02, 15:49-15:57, 15:60-15:62, 15:64:01-15:72, 15:74-15:76, 15:78:01-15:82, 15:84-15:85, 15:87-15:89, 15:91-15:98, 15:101-15:129, 15:131-15:132, 15:134-15:136, 15:138-15:149N, 15:151-15:161, 15:163-15:167, 15:169-15:176, 15:178-15:187, 15:189-15:195, 15:197:01-15:207, 15:209N-15:215, 15:217-15:223, 15:225-15:228, 15:231-15:232, 15:234-15:242:02, 15:244-15:247, 15:249-15:251, 15:254-15:268, 15:270-15:272N, 15:274-15:286, 15:288-15:302N, 15:304N-15:311, 15:314-15:322, 15:325-15:328, 15:330-15:333, 15:335-15:337, 15:340-15:341, 15:343-15:355, 15:357-15:360, 15:362-15:395, 15:397-15:398, 18:01:01:01-18:15, 18:17N-18:25, 18:27-18:40, 18:42-18:60, 18:62-18:121, 18:123, 18:125-18:127, 27:41, 27:107, 35:01:01:01-35:01:45, 35:05:01-35:05:03, 35:07-35:08:08, 35:10-35:11:03, 35:14:01-35:17:02, 35:19-35:21, 35:23-35:30, 35:32:01-35:32:02, 35:35, 35:37, 35:40N-35:43:01, 35:45-35:54, 35:57-35:58, 35:61:01-35:64:02, 35:66-35:69, 35:71-35:72, 35:76-35:80, 35:82, 35:86, 35:89-35:94, 35:97, 35:99-35:105, 35:107-35:108:02, 35:110-35:126, 35:130N-35:135, 35:137-35:148, 35:158-35:159, 35:161, 35:165N-35:166, 35:168, 35:170-35:171, 35:173N-35:178, 35:180,

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information

				35:185-35:192, 35:194, 35:196-35:197, 35:200, 35:202-35:203, 35:206-35:210, 35:212, 35:215-35:219, 35:222, 35:224-35:229, 35:232, 35:238-35:241, 35:244-35:245, 35:247-35:250, 35:252-35:255, 35:259-35:260, 35:262-35:265, 35:268-35:269, 35:271-35:272, 35:275, 35:277, 35:280, 35:283-35:284, 35:286-35:289, 35:293-35:295, 35:297, 35:299-35:308, 35:310, 35:313-35:315, 35:317-35:319, 35:322, 37:35, 37:56, 38:52, 39:07, 39:43, 39:91, 40:03, 40:20, 40:38, 40:52, 40:59-40:60, 40:105, 40:158-40:159, 40:222, 40:267, 40:284, 41:24, 41:30, 42:09, 44:17, 44:43:01-44:43:02, 44:144, 44:230, 45:09, 46:01:01-46:10, 46:12-46:17, 46:19-46:60, 46:62-46:68, 48:02:01-48:02:03, 48:14, 48:23, 48:25, 49:04:01-49:05, 50:33, 51:37, 51:45, 51:63, 51:97, 52:39, 53:01:01-53:03, 53:05-53:06, 53:08:01-53:18, 53:20-53:30, 53:32, 53:34-53:35, 53:37-53:41, 53:43, 55:14, 55:23, 55:32, 55:68, 56:03, 56:09, 56:18, 56:31-56:32, 56:50, 57:01:01-57:01:22, 57:06, 57:08, 57:10-57:11, 57:13-57:16, 57:18-57:27, 57:29-57:31, 57:33-57:38, 57:40-57:41, 57:43-57:45, 57:47-57:56, 57:58-57:62, 57:64-57:65, 57:67:01-57:69, 57:71-57:75, 57:77-57:79N, 57:81, 57:83, 58:01:01:01-58:02:02, 58:04-58:07, 58:09-58:19, 58:21-58:26, 58:29, 58:31N-58:33, 58:35-58:64, 58:66-58:72N, 58:74-58:81
<b>9</b>	200 bp	1070 bp	*54:09	*07:48, 07:202 <sup>w</sup> , 07:209, 07:223, 07:261 <sup>w</sup> , 08:13, 08:25, 08:40 <sup>w</sup> , 08:55, 13:10-13:11, 13:71, 15:05:01-15:05:02, 15:31, 15:48, 15:52, 15:55, 15:91, 15:107, 15:114, 15:123-15:124, 15:136, 15:151, 15:185-15:186, 15:188, 15:224, 15:235, 15:237 <sup>w</sup> , 15:275:01-15:275:02, 15:332, 15:348, 15:383, 15:396, 18:01:01:01-18:01:05, 18:01:07-18:01:24, 18:03-18:07:02, 18:09-18:12:02, 18:13 <sup>w</sup> , 18:14, 18:17N, 18:20, 18:23N-18:26, 18:28-18:29, 18:31-18:44:01, 18:45-18:51, 18:53-18:55, 18:58-18:100, 18:102-18:104, 18:106-18:112, 18:114-18:123, 18:125-18:127, 27:07:01-27:07:05, 27:11, 27:32-27:34, 27:43, 27:70, 27:125, 35:05:01-35:05:03, 35:22, 35:31-35:32:02, 35:51, 35:66 <sup>w</sup> , 35:68:02, 35:72, 35:89, 35:97, 35:114, 35:151, 35:199, 35:234, 35:251, 38:01:01-38:09, 38:11-38:19, 38:21, 38:23, 38:25-38:29, 38:31, 38:33-38:43, 38:45-38:63, 39:01:01:01-39:01:01:04, 39:01:03-39:05:02, 39:07, 39:10:01-39:10:02, 39:12-39:17, 39:19:01-39:20, 39:22-39:23, 39:25N-39:32, 39:37-39:41, 39:43-39:49, 39:51-39:56, 39:58-39:59, 39:61, 39:63, 39:65-39:75, 39:77-39:81, 39:84-39:87N, 39:89, 39:91-39:101, 39:103-39:106, 39:108, 39:110-39:111, 39:113-39:117, 40:01:01-40:01:03, 40:01:05-40:01:11, 40:01:13-40:02:08, 40:02:10-40:03, 40:07-40:11:01, 40:12-40:14:03, 40:18-40:22N, 40:24-40:25,



101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information

				40:27:01-40:27:02, 40:29, 40:31, 40:33, 40:35:01-40:40, 40:42-40:43, 40:45-40:50, 40:52, 40:54-40:58, 40:61-40:63, 40:65-40:67, 40:69, 40:71-40:74, 40:76-40:82, 40:84-40:85, 40:87:01-40:92, 40:94, 40:97, 40:99, 40:101-40:102, 40:104-40:108, 40:111-40:119, 40:121-40:123, 40:124:02, 40:126, 40:128, 40:130:01-40:130:02, 40:132-40:135, 40:138-40:142N, 40:144N-40:147, 40:149-40:157, 40:163-40:164, 40:166, 40:168-40:172, 40:175-40:176, 40:178-40:182, 40:184-40:189, 40:191-40:197, 40:199-40:202, 40:204-40:224, 40:226-40:229, 40:232-40:242, 40:246-40:248, 40:250-40:255, 40:257 <sup>w</sup> , 40:258, 40:260-40:267, 40:271-40:274, 40:276-40:278, 40:280-40:293, 40:296-40:297, 40:299-40:305, 40:308, 40:310, 40:312, 40:314-40:316, 40:319-40:323, 40:325-40:329, 40:331-40:336, 40:338N, 44:31, 44:54, 44:65, 44:82, 44:135, 44:184, 46:06, 46:13:01-46:13:03, 46:19, 46:21:01-46:21:02, 46:26, 46:43, 48:01:01-48:01:06, 48:03:01, 48:04:01-48:04:02, 48:06-48:07, 48:09-48:14, 48:16, 48:18, 48:20, 48:22-48:23, 48:24 <sup>w</sup> , 48:27-48:40, 51:81, 51:148, 51:194, 53:14, 55:04, 55:08, 55:49, 55:51, 56:02:01-56:02:02, 56:04, 56:10, 56:18, 56:31, 56:51 <sup>w</sup> , 57:83, 58:16:01, 58:18, 58:20, 58:27, 67:01:01-67:07, 81:01-81:08, <b>A*02:01:87<sup>w</sup>, C*02:03, C*03:296</b>
<b>10</b>	225 bp	1070 bp	*54:10, 54:20, 54:33	*07:78, 07:84, 13:18, 13:31, 13:41, 15:04:01:01-15:04:04, 15:137, 15:303, 35:265, 39:33, 40:161, 46:32, 49:41, 50:47, 51:05, 51:29, 51:54, 51:61:01-51:61:02, 51:82, 51:197, 52:21, 52:24, 55:09, 55:21, 55:37, 55:52, 56:43, <b>C*12:183</b>
<b>11</b>	185 bp	1070 bp	*54:11, 54:22	*40:298
<b>12</b>	150 bp	1070 bp	*54:12	*59:06
<b>13</b>	135 bp	1070 bp	*54:13	<b>C*03:217</b>
<b>14</b>	210 bp	<b>800 bp</b>	*54:07	*55:64
<b>15<sup>s</sup></b>	95 bp	1070 bp	*54:14-54:16	*07:84, 13:04, 13:35, 13:72, 15:04:01:01-15:04:04, 15:16:01:01-15:16:03, 15:67, 15:95, 15:155, 15:222, 15:254, 15:293, 15:310, 15:362, 35:37, 35:235, 35:265, 40:44, 40:159, 41:21, 44:20, 44:47, 44:100, 44:197, 45:09, 46:32, 49:04:01-49:05, 50:33, 50:39, 51:37, 51:90, 51:92:01-51:92:02, 51:197, 52:12, 52:26, 55:23, 55:27, 55:46, 55:68, 56:50, <b>C*07:463, C*12:183</b>
<b>16</b>	210 bp 340 bp	1070 bp	*54:18 *54:17	
<b>17</b>	210 bp	1070 bp	*54:20, 54:33 <sup>w</sup>	*07:78, 07:84, 13:16, 13:31 <sup>w</sup> , 13:48, 13:62, 14:37, 15:04:01:01 <sup>w</sup> -15:04:04 <sup>w</sup> , 15:16:01:01-15:16:03, 15:42, 15:67, 15:95, 15:137 <sup>w</sup> , 15:254, 15:293, 15:303 <sup>w</sup> , 15:310, 15:362, 27:153, 35:265 <sup>w</sup> , 40:95, 40:148, 40:161, 46:32 <sup>w</sup> , 49:01:01, 49:01:03-49:10, 49:12-49:14, 49:16-49:43, 50:01:01-50:02, 50:04-50:11,



101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information

				50:13-50:16, 50:18-50:20, 50:31-50:46, 50:47 <sup>w</sup> , 51:01:01:01-51:03, 51:07:01-51:07:02, 51:11N-51:14, 51:16-51:18, 51:21-51:24:05, 51:26-51:30, 51:32-51:35, 51:37-51:39, 51:41N, 51:43, 51:48-51:53, 51:55, 51:57-51:58, 51:60, 51:61:01 <sup>w</sup> -51:61:02 <sup>w</sup> , 51:63, 51:65-51:71, 51:74-51:80, 51:82-51:86, 51:88-51:90, 51:92:01-51:92:02, 51:94-51:96, 51:98N-51:107, 51:109-51:114, 51:116-51:121, 51:123-51:134, 51:136-51:138, 51:140, 51:142-51:147, 51:149N-51:152, 51:154-51:156, 51:158:01-51:180, 51:182-51:193, 51:195-51:208, 52:01:01:01-52:02:02, 52:04-52:09, 52:11-52:18, 52:20, 52:21 <sup>w</sup> , 52:22-52:43, 52:44 <sup>w</sup> , 52:45-52:61, 55:01:01-55:01:06, 55:01:08-55:01:16, 55:03, 55:05, 55:09, 55:11, 55:15, 55:17, 55:21 <sup>w</sup> , 55:24-55:25, 55:28-55:29, 55:31, 55:33, 55:36, 55:38, 55:40, 55:44-55:45, 55:52-55:55N, 55:58-55:60, 55:64, 55:66, 55:68, 55:73-55:76, 55:78, 56:05:01-56:06, 56:21, 56:25, 56:37, 58:08:01-58:08:02, 78:01:01-78:03, 78:05-78:07, 78:09, <b>C*12:183<sup>w</sup></b>
<b>18</b>	295 bp	1070 bp	*54:21	*40:149, 41:22, 49:25, 55:10, 56:16, 57:58, 57:80, 67:06 <sup>?</sup> -67:07 <sup>?</sup> , 82:01-82:03
<b>19</b>	230 bp	1070 bp	*54:23	*08:158
<b>20</b>	205 bp	1070 bp	*54:24	
<b>21</b>	250 bp	1070 bp	*54:32	
<b>22<sup>B</sup></b>	-	-	<b>Negative Control</b>	

<sup>1</sup>Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-B\*54 SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length. Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>For several HLA Class I alleles 1<sup>st</sup> and/or 4<sup>th</sup> exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

**Lot No.: 7E8**

**Lot-specific information**

<sup>4</sup>Due to the sharing of sequence motifs between HLA-B alleles, non-HLA-B\*54 alleles will be amplified by primer mixes 1 to 6, 8 to 12, 14, 15 and 17 to 19. In addition, a few HLA-A and HLA-C alleles will be amplified by primer mixes 3 to 5, 9, 13, 15 and 17.

<sup>5</sup>HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

<sup>6</sup>Primer mix 3 may give rise to a lower yield of HLA-specific PCR product than the other HLA-B\*54 primer mixes.

<sup>7</sup>Primer mix 4 may have tendency of unspecific amplification.

<sup>8</sup>Primer mix 22 contains a negative control, which will amplify more than 95% of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 430 base pairs.

‘w’, might be weakly amplified.

‘?’ , nucleotide sequence of the primer matching region not known.

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information  
**PRIMER SPECIFICATION**

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec. PCR product	215	105	160	160	180	105	140	280	200	225	185	150
Length of int. pos. control <sup>1</sup>	<b>800</b>	1070	1070	1070	1070	1070	1070	1070	1070	1070	1070	1070
5'-primer(s) <sup>2</sup>	1 <sup>st</sup> I	357	106	103	420	357	106	419	369	357	357	206
	5'-CAg 3'	5'-Tgg 3'	5'-CCA 3'	5'-CCT 3'	5'-TTA 3'	5'-Tgg 3'	5'-CCA 3'	5'-gTC 3'	5'-TAC 3'	5'-Tgg 3'	5'-Tgg 3'	5'-Agg 3'
				103								
				5'-CCT 3'								
				110								
				5'-gTT 3'								
3'-primer(s) <sup>3</sup>	175	420	226	226	553	419	207	3 <sup>rd</sup> I	527	539	499	317
	5'-CCg 3'	5'-gCT 3'	5'-CAC 3'	5'-CAC 3'	5'-CTA 3'	5'-CgT 3'	5'-TCC 3'	5'-TAT 3'	5'-CCA 3'	5'-TCC 3'	5'-ggA 3'	5'-ggA 3'
					559	553			527			
					5'-CAg 3'	5'-CTA 3'			5'-CCA 3'			
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

Well No.	13	14	15	16	17	18	19	20	21
Length of spec. PCR product	135	210	95	210	210	295	230	205	250
Length of int. pos. control <sup>1</sup>	1070	<b>800</b>	1070	1070	1070	1070	1070	1070	1070
5'-primer(s) <sup>2</sup>	133	106	357	89	357	15	106	106	802
	5'-CCg 3'	5'-CCA 3'	5'-Tgg 3'	5'-gAA 3'	5'-Tgg 3'	5'-gCA 3'	5'-CCA 3'	5'-CCA 3'	5'-Agg 3'
				709					
				5'-Agg 3'					
3'-primer(s) <sup>3</sup>	226	275	412	259	527	142	294	272	916
	5'-CAC 3'	5'-CCA 3'	5'-gTC 3'	5'-gTT 3'	5'-CCT 3'	5'-TgA 3'	5'-CgC 3'	5'-TgA 3'	5'-gAT 3'
			412	916					
			5'-gTC 3'	5'-gAT 3'					
Well No.	13	14	15	16	17	18	19	20	21

<sup>1</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>2</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>3</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-B*54 SSP subtyping kit <sup>2</sup>																				
				Well																
				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	
				Prod. No.:	201203501	201203502	201203503	201327004	201203505	201203506	201203507	201203508	201203509	201203510	201203511	201203512	201327013	201203514	201203515	201203516
	IHWC cell line <sup>1</sup>		B*																	
1	9001 SA		*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707		*52:01 *73:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
3	9011 E4181324		*52:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
4	9275 GU373		*15:10 *53:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
5	9009 KAS011		*37:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM		*39:01 *51:01	-	-	-	-	-	+	-	-	-	+	-	-	-	-	-	-	-
7	9020 QBL		*18:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
8	9025 DEU		*35:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
9	9026 YAR		*38:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
10	9107 LKT3		*54:01	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT		*44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB		*57:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
13	9025 JESTHOM		*27:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA		*15:01 *15:20	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
15	9075 DKB		*40:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
16	9037 SWEIG007		*40:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540		*08:01 *55:01	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257 32367		*14:01 *56:01	-	+	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16		*18:01	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-
20	9059 SLE005		*40:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
21	9064 AMALA		*15:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
22	9056 KOSE		*35:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL		*40:02 *56:02	-	-	-	-	+	-	-	-	-	+	-	-	-	-	-	-	-
24	9035 JBUSH		*38:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
25	9049 IBW9		*14:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285 WT49		*58:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
27	9191 CH1007		*07:05 *51:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
28	9320 BEL5GB		*44:02 *44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU		*44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH		*42:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF		*18:01	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-
32	9297 HAG		*41:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B		*40:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
34	9104 DHIF		*38:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
35	9302 SSTO		*44:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17		*15:01 *35:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
37	9065 HHKB		*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL		*15:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
39	9315 CML		*08:01 *27:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199		*13:02 *46:01	-	+	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
41	9055 H0301		*14:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066 TAB089		*46:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
43	9076 T7526		*46:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
44	9057 TEM		*38:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
45	9239 SHJO		*42:01 *50:01	-	+	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU		*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO		*51:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
48	9303 TER-ND		*35:01 *44:03	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: 7E8

Lot-specific information

CELL LINE VALIDATION SHEET									
HLA-B*54 SSP subtyping kit <sup>2</sup>									
				Well					
				17	18	19	20	21	
				Prod. No.:	201203517	201327018	201203519	201203520	201553221
	IHWC cell line <sup>1</sup>	B*							
1	9001 SA	*07:02		-	-	-	-	-	
2	9280 LK707	*52:01	*73:01	+	-	-	-	-	
3	9011 E4181324	*52:01		+	-	-	-	-	
4	9275 GU373	*15:10	*53:01	-	-	-	-	-	
5	9009 KAS011	*37:01		-	-	-	-	-	
6	9353 SM	*39:01	*51:01	+	-	-	-	-	
7	9020 QBL	*18:01		-	-	-	-	-	
8	9025 DEU	*35:01		-	-	-	-	-	
9	9026 YAR	*38:01		-	-	-	-	-	
10	9107 LKT3	*54:01		-	-	-	-	-	
11	9051 PITOUT	*44:03		-	-	-	-	-	
12	9052 DBB	*57:01		-	-	-	-	-	
13	9025 JESTHOM	*27:05		-	-	-	-	-	
14	9071 OLGA	*15:01	*15:20	-	-	-	-	-	
15	9075 DKB	*40:01		-	-	-	-	-	
16	9037 SWEIG007	*40:02		-	-	-	-	-	
17	9282 CTM3953540	*08:01	*55:01	+	-	-	-	-	
18	9257 32367	*14:01	*56:01	-	-	-	-	-	
19	9038 BM16	*18:01		-	-	-	-	-	
20	9059 SLE005	*40:01		-	-	-	-	-	
21	9064 AMALA	*15:01		-	-	-	-	-	
22	9056 KOSE	*35:03		-	-	-	-	-	
23	9124 IHL	*40:02	*56:02	-	-	-	-	-	
24	9035 JBUSH	*38:01		-	-	-	-	-	
25	9049 IBW9	*14:02		-	-	-	-	-	
26	9285 WT49	*58:01		-	-	-	-	-	
27	9191 CH1007	*07:05	*51:01	+	-	-	-	-	
28	9320 BEL5GB	*44:02	*44:03	-	-	-	-	-	
29	9050 MOU	*44:03		-	-	-	-	-	
30	9021 RSH	*42:01		-	-	-	-	-	
31	9019 DUCAF	*18:01		-	-	-	-	-	
32	9297 HAG	*41:02		-	-	-	-	-	
33	9098 MT14B	*40:01		-	-	-	-	-	
34	9104 DHIF	*38:01		-	-	-	-	-	
35	9302 SSTO	*44:02		-	-	-	-	-	
36	9024 KT17	*15:01	*35:01	-	-	-	-	-	
37	9065 HHKB	*07:02		-	-	-	-	-	
38	9099 LZL	*15:01		-	-	-	-	-	
39	9315 CML	*08:01	*27:05	-	-	-	-	-	
40	9134 WHONP199	*13:02	*46:01	-	-	-	-	-	
41	9055 H0301	*14:02		-	-	-	-	-	
42	9066 TAB089	*46:01		-	-	-	-	-	
43	9076 T7526	*46:01		-	-	-	-	-	
44	9057 TEM	*38:01		-	-	-	-	-	
45	9239 SHJO	*42:01	*50:01	+	-	-	-	-	
46	9013 SCHU	*07:02		-	-	-	-	-	
47	9045 TUBO	*51:01		+	-	-	-	-	
48	9303 TER-ND	*35:01	*44:03	-	-	-	-	-	

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

**Lot No.: 7E8**

**Lot-specific information**

<sup>1</sup>The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

<sup>2</sup>The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 4, 7, 11 to 14, 16 and 19 to 21 were available. The specificities of the primers in primer solutions 4, 11, 12 and 16 were tested by separately adding one or two additional 5'-primers, respectively one or two additional 3'-primers. In primer solutions 7, 14, 19 and 20 it was only possible to test the 5'-primer, the 3'-primer was not possible to test. In primer solutions 13 and 21 it was only possible to test the 3'-primer, the 5'-primer was not possible to test. One 5'-primer in primer solutions 4 and 16 and one 3'-primer in primer solutions 5 and 6 was not possible to test. In addition, one 3'-primer in primer solution 15 was tested by separately adding an additional 5'-primer.

101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information



101.569-06 – including *Taq* polymerase, IFU-01  
101.569-06u – without *Taq* polymerase, IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **7E8**

Lot-specific information

**ADDRESSES:**

**Manufacturer:**

**Olerup SSP AB**, Franzengatan 5, SE-112 51 Stockholm, Sweden.

**Tel:** +46-8-717 88 27

**Fax:** +46-8-717 88 18

**E-mail:** [info-ssp@olerup.com](mailto:info-ssp@olerup.com)

**Web page:** <http://www.olerup-ssp.com>

**Distributed by:**

**Olerup GmbH**, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

**Tel:** +43-1-710 15 00

**Fax:** +43-1-710 15 00 10

**E-mail:** [support-at@olerup.com](mailto:support-at@olerup.com)

**Web page:** <http://www.olerup.com>

**Olerup Inc.**, 901 S. Bolmar St., Suite R, West Chester, PA 19382

**Tel:** 1-877-OLERUP1

**Fax:** 610-344-7989

**E-mail:** [info.us@olerup.com](mailto:info.us@olerup.com)

**Web page:** <http://www.olerup.com>

For information on *Olerup* SSP distributors worldwide, contact **Olerup GmbH**.